Phoenix personal injury attorney Stephen I. Leshner has been selected to the 2014 Arizona Super Lawyers list, for the seventh consecutive year. Each year, no more than five percent of the lawyers in the state are selected by the research team at Super Lawyers to receive this honor. Super Lawyers, a Thomson Reuters business, is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high degree of peer recognition and professional achievement. The annual selections are made using a patented multiphase process that includes a statewide survey of lawyers, an independent research evaluation of candidates and peer reviews by practice area. The result is a credible, comprehensive and diverse listing of exceptional attorneys. The Super Lawyers lists are published nationwide in Super Lawyers Magazines and in leading city and regional magazines and newspapers across the country. Super Lawyers Magazines also feature editorial profiles of attorneys who embody excellence in the practice of law. For more information about Super Lawyers, visit SuperLawyers.com.
Endo Health Solutions Inc., the parent company of American Medical Systems, Inc., (AMS) is under investigation relating to its pelvic mesh products. The company has received subpoenas from a number of states in the investigation. Endo revealed this information in a SEC filing last month that warned investors that the "strain of pelvic mesh litigation" threatens its unit's women's health business. AMS is facing thousands of lawsuits in multi-district litigations over the products, and said in the filing that the company is now facing investigation by a number of states, and is cooperating with the investigation.
In the just published "Showtime", a book about the Los Angeles Lakers of the 1980's, by best-selling author Jeff Pearlman, I was interviewed about a case I handled a long time ago. While all my cases are important to me and my clients, this case received a disproportionate amount of publicity, if only because of the identity of the Defendant. As reported in the book:
Biomet has agreed to pay a base rate of $200,000 each to hundreds of people who received artificial hips that were later replaced, which depending on individual circumstances, can be adjusted upward or downward.
Transvaginal Mesh (TVM): The first bellwhether trial in the MDL against Johnson & Johnson (Ethicon) began on February 10, 2014. The first bellwhether trial against American Medical Systems (AMS) in the MDL is scheduled for April 17, 2014. Stephen I. Leshner, P.C. has a number of TVM clients with complaints filed in the MDL against these Defendants, and others, and we are anxiously awaiting the results of these trials.
An op-ed piece in titled "Don't Ask Your Doctor About Low-T" in today's New York Times discusses the link between prescription drugs for low testosterone and heart attack in otherwise healthy men. See the link to the article below. If you or someone close to you has suffered a heart attack or other serious cardiac event after taking a prescription drug for low testosterone, please call Phoenix Arizona accident injury product liability attorney Stephen I. Leshner for a free consultation.
More than 30,000 Transvaginal mesh (TVM) lawsuits have been filed in the United States District Court, Southern District of West Virginia in Multi-District Litigation (MDL). An MDL consolidates all litigation, so that it can be efficiently litigated at the same time by all the parties in front of one Judge. For example, I filed numerous TVM cases in Arizona, which were transferred to the MDL in West Virginia. The Defendants in these cases are transvaginal mesh manufacturers C.R. Bard, Ethicon, Inc. (Johnson & Johnson), American Medical Systems, Inc., Coloplast Corporation, Cook Medical Inc. and Boston Scientific Corporation, and an MDL has been formed for cases against each manufacturer. Additionally, several thousand TVM cases are pending in state courts around the country.
Lipitor is one of the most common brand name medications on the market. According to several lawsuits filed in 2013, Pfizer, the manufacturer of Lipitor, knew or reasonably should have known in 1997 that there was a connection between Lipitor and diabetes before the drug was placed on the market; however, there was no warning placed on the label until 2012.